Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.52 |
| ▸ | GHSR | Q92847 | 8/20 | 0.48 |
| ▸ | KISS1R | Q969F8 | 4/20 | 0.46 |
| ▸ | MMP2 | P08253 | 3/20 | 0.46 |
| ▸ | MMP9 | P14780 | 2/20 | 0.46 |
| ▸ | MMP8 | P22894 | 2/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2183785 | 0.89 | GHSR (0.48) | GHSRMMP2MMP9MMP8MMP1 | |
| SCHEMBL2195079 | 0.88 | ERAP2 (0.49) | KISS1RMMP2MMP9MMP8MMP1 | |
| SCHEMBL30590798 | 0.86 | ERAP2 (0.56) | GHSR | |
| SCHEMBL30590781 | 0.86 | ERAP2 (0.56) | GHSR | |
| SCHEMBL30259624 | 0.85 | ERAP2 (0.58) | GHSR | |
| SCHEMBL29663506 | 0.84 | GHSR (0.52) | UTS2RGHSR | |
| SCHEMBL31003037 | 0.83 | UTS2R (0.54) | UTS2RGHSR | |
| SCHEMBL30590790 | 0.83 | ECE1 (0.53) | UTS2RGHSR | |
| SCHEMBL31473234 | 0.81 | NPBWR1 (0.53) | GHSRKISS1R | |
| SCHEMBL31473233 | 0.81 | NPBWR1 (0.53) | GHSRKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190070251-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS | 2019-03-07 | — | — | US | disclosed |
| US-9682153-B2 | Polymer conjugates of therapeutic peptides | NEKTAR THERAPEUTICS (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS | 2016-01-28 | — | — | US | disclosed |
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | UTS2R 1024/4885GHSR 1894/4885KISS1R 1433/4885 |
| US-20190070251-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | UTS2R 1024/4885GHSR 1894/4885KISS1R 1433/4885 |
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | DNPEP, VIP, PTMS | UTS2R 719/4885GHSR 1457/4885KISS1R 1880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.